The debate over what truly qualifies as an Oral Rehydration Solution has exploded into a national controversy, drawing doctors, regulators, and corporations into a tug-of-war between science, ethics, and business. What started as a technical question over a label has become a question of conscience, where the life of a dehydrated child and the marketing ambitions of a multinational company collide in the most unsettling way.

It began with the Food Safety and Standards Authority of India’s (FSSAI) directive issued in mid-October 2025, banning companies from using the term “ORS” on products that do not meet the World Health Organization (WHO) standards for Oral Rehydration Solution. These WHO-compliant formulations are carefully balanced mixtures of glucose and salts designed to save lives in cases of dehydration caused by diarrhoea i.e. a common but deadly threat, especially for children. Yet, for years, shelves across India have been lined with bottles and pouches bearing the “ORS” label. Colorful beverages branded as health drinks, containing extra vitamins, sugars, and flavors that dilute their true therapeutic purpose.

Among these was ORSL, a product of JNTL Consumer Health India, a subsidiary of Kenvue Inc., which spun off from Johnson & Johnson in 2023. Another was RebalanzVitORS, marketed by Dr. Reddy’s Laboratories. Both carried disclaimers clarifying that they were not WHO-recommended formulations, but the branding was deliberate and designed to borrow the credibility of medical-grade ORS while serving as over-the-counter drinks for consumers seeking “rehydration.”

When FSSAI finally acted, it seemed like a long-overdue move to protect public health and restore clarity. However, what followed left many medical professionals stunned. JNTL challenged the directive in the Delhi High Court, which on procedural grounds granted an interim stay, allowing the company to continue selling ORSL-branded beverages until FSSAI reviewed their representation. What could have been a brief pause for due process quickly became a symbol of regulatory delay and for doctors like Dr. Sivaranjani Santosh, it was a deeply personal moment of outrage.

Dr. Santosh, a Hyderabad-based paediatrician who has spent years campaigning for safe hydration practices, spoke with an urgency that cut through the bureaucracy. For her, this wasn’t about semantics. It was about life and death. “Children die of diarrhoea not because we don’t have a cure,” she wrote on X (formerly Twitter), “but because we keep confusing parents with products that look like medicine but act like marketing gimmicks.”

Her words carried weight, because behind every “nutritional drink” that mimics ORS lies a story of misinformation. Parents, desperate to hydrate their sick children, pick up bottles labeled with the familiar “ORS” acronym, assuming they are safe substitutes for the life-saving WHO formulation. What they often get instead is a sweetened beverage that fails to restore electrolytes properly and, in cases of severe dehydration, can even worsen the condition.

Dr. Santosh’s fight against such products has been long and relentless. She has repeatedly urged both companies and regulators to exercise moral responsibility arguing that disclaimers are meaningless when labels themselves mislead. “If a mother in a remote village thinks she’s buying medicine but is actually giving her child a sugary drink, that’s not an innocent mistake. That’s negligence disguised as business,” she said in one of her statements to the media.

Her frustration deepened when the court’s order appeared to give companies an extended timeline. “It’s unfortunate that FSSAI is taking so long,” she told reporters, highlighting that the High Court had expected a quick review within a week. Instead, the deadline stretched, allowing companies to continue selling until October 31. “They are clearing stocks while misleading parents and endangering children even those with diabetes. I find it very disappointing that FSSAI hasn’t acted decisively.”

The controversy has revived old wounds within India’s public health community. For decades, paediatricians and community doctors have worked tirelessly to educate rural families on how to prepare and administer Oral Rehydration Solution which is a mixture that, when used correctly, can save millions of children from dehydration-related deaths. WHO’s ORS formula is a triumph of simple science: low-cost, accessible, and life-saving. To see that name exploited for profit has felt like a betrayal to many in the medical fraternity.

Meanwhile, the Delhi High Court’s own remarks hinted at unease. During hearings, the bench clarified that its consent order was “passed to enable the FSSAI to take the requisite steps,” and not to give manufacturers a free pass to continue production. The judges made it clear that if FSSAI failed to act promptly, the court would step in to restrain companies from manufacturing non-compliant products. Yet the ambiguity of interim relief allowed businesses to keep operations running and that, to critics, is where the system failed.

This episode has exposed a deeper problem in India’s health regulatory framework that extends beyond beverages or brand names. It’s the gap between intention and enforcement, where consumer safety laws exist but their execution lags behind corporate agility. Companies with vast legal resources can challenge or delay compliance, while regulators are bogged down by procedural formality and political caution.

The FSSAI, established to ensure the safety and authenticity of food and nutrition products, has repeatedly been accused of acting reactively rather than proactively. In this case, the directive came years after ORSL and similar drinks had already penetrated the market, enjoyed celebrity endorsements, and shaped consumer perception. The problem wasn’t that FSSAI didn’t know it was that it didn’t move fast enough.

In contrast, doctors like Dr. Santosh have been raising alarms for nearly a decade, often facing corporate pushback and social media backlash. Her advocacy isn’t academic, it’s emotional. In her clinics, she has treated children whose parents unknowingly relied on flavored “ORS” drinks during bouts of diarrhoea, delaying proper treatment until it was too late. For her, this controversy is personal because it represents a preventable tragedy repeated countless times.

The irony is painful. A product meant to represent medical trust has been turned into a marketing asset. In many ways, the “ORSL” name borrowed the credibility of decades of public health education and then sold it back to consumers as a lifestyle beverage. When a trusted regulatory body delays taking firm action, it inadvertently validates the confusion.

FSSAI’s hesitation has broader implications too. When health regulations are seen as negotiable, it weakens public trust across all domains from baby food to supplements, from protein drinks to “immunity boosters.” The fallout isn’t limited to this one product; it creates a dangerous precedent where corporate persuasion can overshadow public welfare.

The Delhi High Court’s warning to FSSAI was clear: act quickly or face judicial restraint. Yet, as the case dragged into late October, it became evident that the battle between consumer protection and corporate interest is far from over. The regulator’s final decision, expected by the end of the month, could determine whether India’s market prioritizes scientific integrity or commercial branding.

For the medical community, this is more than a regulatory tussle, it’s a moral reckoning. Dr. Santosh’s fight, often waged through social media posts and public appeals, represents a rare instance where medical ethics confront corporate might. She has been urging parents, pharmacies, and even hospitals to verify whether the ORS products they use are WHO-compliant. “Science cannot be selective,” she said. “If we allow misleading terms on labels, we are letting marketing write our medical vocabulary.”

Meanwhile, among parents and healthcare workers, the confusion continues. Pharmacies still stock bottles labeled “ORS,” and advertisements continue to blur the line between health drink and medical aid. In remote areas where access to proper medical guidance is limited, this confusion can be fatal.

As the deadline for FSSAI’s final decision approaches, the country waits, some with anger, some with hope, and many with disbelief that such a simple issue could grow so large. But perhaps that’s the tragedy of it all: that a name, three letters long, could carry such heavy meaning.

For doctors like Dr. Sivaranjani Santosh, the battle isn’t about corporate politics it’s about reclaiming truth in medicine. For her, ORS isn’t a brand. It’s a promise that should never be diluted, twisted, or sold. And until that promise is protected, the fight continues.

Because somewhere in a clinic, a mother still believes that a bottle labeled “ORS” can save her child when what she really needs is protection from a system that allowed the confusion in the first place.